Articles from IGC Pharma, Inc.

Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London

IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced additional interim data from its ongoing Phase 2 clinical trial evaluating IGC-AD1. The trial focuses on agitation in Alzheimer's as its primary outcome, with cognition assessed as an exploratory outcome. Interim data analysis reveals cognitive improvements in the active treatment group versus the placebo group, marking a meaningful step toward developing a therapy that may influence underlying disease progression.

IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced data that reinforces the therapeutic potential of IGC-AD1 as a disease-modifying treatment for Alzheimer's disease. The data highlights IGC-AD1's promising effects on tau tangles and spatial memory. These results build on earlier data demonstrating IGC-AD1's potential to reduce amyloid plaque.

IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") announced today that the Company is advancing its proprietary formulation, IGC-AD1, toward clinical trials as a potential anti-amyloid disease-modifying treatment for Alzheimer's disease.

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the “Annual Meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 8, 2024, were passed by the requisite vote of the stockholders. Only stockholders of record on the record date of June 28, 2024, were entitled to and requested to vote at the Annual Meeting.

IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced preclinical research demonstrating the therapeutic potential of IGC-1C, a novel small-molecule modulator. The findings show that IGC-1C targets tau protein phase separation, presenting new opportunities for addressing multiple pathways in neurodegenerative disease.

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the first fiscal quarter of 2025 ended June 30, 2024.

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) announces that Alliance Global Partners (AGP) has issued an analyst coverage research report on the Company’s common stock.

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced preclinical data demonstrating TGR-63’s potential as an effective treatment for Alzheimer’s disease. Analysis of the partition coefficient and mass spectrometry of brain tissue in Alzheimer’s murine models both indicate that TGR-63 has the potential to cross the blood-brain barrier in humans. These findings build on earlier results demonstrating TGR-63’s efficacy in reducing amyloid plaque in Alzheimer's mouse models.

IGC Pharma, Inc. (NYSE American: IGC) ("IGC" or the "Company") today announced encouraging preclinical results in an Alzheimer’s mouse model demonstrating the potential of the Company’s therapeutic candidate, TGR-63, to combat Alzheimer's disease.

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, has announced its financial results for the fiscal year ended March 31, 2024 (“Fiscal 2024”).

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, June 27, 2024, at 12:00 pm ET. IGC Pharma management will discuss recent operational achievements as well as upcoming milestones.

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced the publication of a significant research article in the European Society of Medicine Journal. The study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics (“PK”) of delta-9-tetrahydrocannabinol (“THC”) and its active metabolite in Alzheimer’s disease (“AD”) patients.

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer’s at week two compared to placebo.

IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC-AD1, IGC Pharma’s lead therapeutic candidate targeting agitation in Alzheimer’s disease. Recent interim results from the IGC-AD1 Phase 2 trial demonstrated a clinically and statistically significant reduction in agitation compared to placebo in patients with Alzheimer's disease, indicating strong therapeutic potential.

IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (“AAD”).

IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced that Ram Mukunda, CEO, and Claudia Grimaldi, Vice President, will participate in a fire chat at the BENZINGA VIRTUAL HEALTHCARE SUMMIT 2024 (https://www.benzinga.com/events/virtual-healthcare-summit-2024/).

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced the results of preclinical studies investigating its drug candidate TGR-63 as a treatment for Alzheimer's disease. The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets LLC (Ascendiant) has issued an analyst coverage research report on the Company’s common stock.

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced additional positive results of preclinical studies investigating the Company's newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer's disease. Previously disclosed results demonstrate that TGR-63 may successfully alleviate plaque burden in Alzheimer's cell lines and animal models. Plaques are a key hallmark and therapeutic target of Alzheimer's disease.

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) provides details on its drug candidate TGR-63, which targets amyloid-beta plaque and can potentially improve Alzheimer's disease treatment in a significant manner.

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that ClinCloud, a clinical research facility in Florida, has dosed its first patient as part of the Company’s ongoing Phase 2b trial.

IGC Pharma, Inc. (“IGC Pharma” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, announced today that Divisional Direction of Patents, Mexico, has issued a Granting Office Action (GOA) for its treatment of Alzheimer’s disease titled “Method and Composition for Treating CNS Disorder.” The Company is optimistic that the success witnessed in Mexico can pave the way for additional approvals in the U.S. and Europe.

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced that the Company’s management team will participate in Biotech Showcase and BIO Partnering @ JPM, held in-person and scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University’s Center for Research and Training in Artificial Intelligence (“CINFONIA”). The partnership aims to leverage Generative AI (AI) to analyze variations in disease signatures among patients, enabling IGC Pharma to identify individuals more likely to respond to treatment and subsequently accelerate the delivery of treatments to patients.

IGC Pharma, Inc. (“IGC Pharma,” "IGC" or the "Company") (NYSE American: IGC) today announced a Master Cooperation Agreement with the University of Los Andes for the development and adoption of generative AI solutions into the Company’s drug identification, development, and clinical trial processes. IGC Pharma will be focused on advancing various AI initiatives including:

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).

IGC Pharma, Inc. (“IGC,” “IGC Pharma” or the “Company”) (NYSE American: IGC), a visionary clinical-stage pharmaceutical company, is thrilled to announce a significant milestone: the grant of European Patent No. 3193862 by the European Patent Office (“EPO”) for our innovative "Cannabinoid Composition and Method for Treating Pain."

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 18, 2023 (the “Annual Meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 26, 2023, were passed by the requisite vote of the stockholders. Only stockholders of record on the record date of June 21, 2023, were entitled to and requested to vote at the Annual Meeting.

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended June 30, 2023, which is the first quarter of the Company’s 2024 fiscal year.

IGC Pharma, Inc (NYSE American: IGC) (“IGC” or the “Company”), today announced the addition of an important trial site at the University of Puerto Rico network as an expansion of the Company’s ongoing Phase 2 clinical trial investigating lead drug asset, IGC-AD1, as a treatment for lowering agitation in patients with Alzheimer’s disease.

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company, today announced that it is presenting 6 in-person posters highlighting data from its Phase 1 clinical trials investigating the Company’s lead therapeutic candidate, IGC-AD1, at the Alzheimer’s Association International Conference (“AAIC”) being held July 16-20, 2023, in Amsterdam, Netherlands.

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”).

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company, has secured a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co., Ltd. (“O-Bank” or the “Bank”). This funding will support IGC’s working capital needs primarily related to its Alzheimer’s research.

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a strategic investment from four investment funds managed by Bradbury Asset Management (Hong Kong) Limited (“Bradbury”) who is a leading asset management firm with over $2 billion in managed assets. This investment, along with additional contributions from three unrelated investors, has resulted in approximately $3 million in gross proceeds, further strengthening IGC’s working capital. The funds support the advancement of the Company’s Phase-2 clinical trial of IGC-AD1, the Company’s promising investigational drug candidate designed to address agitation in dementia caused by Alzheimer's disease.

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that it has received a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (IGC-501). The formulation also received an intent to grant from the European Patent Office. With these awards, and a previous one, the formulation for treating seizures is protected in the U.S., Canada, and certain European countries.